Feed BSLN.SW
BS

Basilea Pharmaceutica AG BSLN.SW SIX · Healthcare · Switzerland

CHF 72.70 +0.00% +CHF 0.00

Market cap
CHF 898.6M
Enterprise value
CHF 958.1M
P/E
22.4x
Forward P/E
9.7x
PEG
-
P/S
3.9x
P/FCF
15.2x
EV/EBITDA
17.9x
ROIC
19.3%
Gross margin
83.1%
Net margin
17.3%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
1.1x
Beta
0.43
Free float
92.1%

Sector

Healthcare

Industry

Biotechnology

CEO

David Veitch

Employees

200

Headquarters

Allschwil

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Earnings per share grew by 45% a year over the last 3 years.
  • What to watch: Earnings per share swing sharply from year to year.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 CHF of revenue, 17 CHF is left as net profit.
  • What speaks for it: It earns 19 CHF a year on every 100 CHF of invested capital.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy